Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nilotinib in patients with metastatic melanoma harboring KIT gene aberration.

Investigational new drugs - 1 Oct 2012

Cho Jin Hyun, Kim Kyoung Mee, Kwon Miyeon, Kim Jung Han, Lee Jeeyun

Abstract excerpt

PURPOSE: Patients with metastatic melanoma have a poor prognosis and few treatment options are available. We evaluated the anti-tumor activity and safety of nilotinib, a KIT inhibitor, in patients with metastatic melanoma harboring KIT alterations, either mutations or amplifications. PATIENTS AND METHODS: This study was open-label, single center, prospective phase II clinical trial. Between October 2009 and April...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Gene Amplification

Share to Melanoma

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Source

Identifiers

PMID: 22068222
DOI: 10.1007/s10637-011-9763-9

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nilotinib in patients with metastatic melanoma harboring KIT gene aberration.PMID 22068222Read ↗

Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).Semantic proximity Read ↗

A potential role for nilotinib in KIT-mutated melanoma.Semantic proximity Read ↗

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.Semantic proximity Read ↗

STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.Semantic proximity Read ↗

Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.Semantic proximity Read ↗

Imatinib in c-KIT-mutated metastatic solid tumors: A multicenter trial of Korean Cancer Study Group (UN18-05 Trial).Semantic proximity Read ↗

C-Kit non-mutated metastatic melanoma showing positive response to Nilotinib.Semantic proximity Read ↗

KIT and Melanoma: Biological Insights and Clinical Implications.Semantic proximity Read ↗

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.Semantic proximity Read ↗

JAK-ing up the Response to KIT Inhibition.Semantic proximity Read ↗

Lymph node metastatic melanoma from ungual melanoma: Identification of somatic mutations in KIT and LZTR1.Semantic proximity Read ↗

Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.